{"id":86470,"date":"2026-06-18T04:14:19","date_gmt":"2026-06-18T04:14:19","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/86470\/"},"modified":"2026-06-18T04:14:19","modified_gmt":"2026-06-18T04:14:19","slug":"sanity-group-deepens-swiss-footprint-with-astrasana-distribution-deal","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/86470\/","title":{"rendered":"Sanity Group Deepens Swiss Footprint With Astrasana Distribution Deal"},"content":{"rendered":"

Sanity Group<\/a> has announced a new distribution partnership with Swiss cannabis operator Astrasana Holding AG<\/a>, further expanding its footprint in the closely watched Swiss market.\u00a0<\/p>\n

Now a subsidiary of Canadian producer Organigram, following the completion of its \u20ac250m acquisition<\/a> earlier this year, Sanity has signed a new deal with Bogen Pharma GmbH<\/a>, a subsidiary of Astrasana, to supply its Avaay Medical<\/a> cannabis products to Swiss patients.\u00a0<\/p>\n

The deal, announced on 15 June, gives Avaay Medical access to Astrasana\u2019s established network of more than 20 Swiss pharmacy partners.\u00a0<\/p>\n

Swiss supply strain<\/p>\n

Switzerland\u2019s medical cannabis market currently serves approximately 6,000 patients. While a fraction of the size, it mirrors its German neighbour in the dominance of flower products and the prominence of telemedicine as a growth driver.\u00a0<\/p>\n

However, the gravitational pull of Germany\u2019s meteoric growth has drawn flower supply away from adjacent markets.<\/p>\n

According to Astrasana\u2019s Managing Director, Yves Antoniazzi, when the Swiss market also began accelerating meaningfully in 2025, existing supply relationships proved inadequate.\u00a0<\/p>\n

\u201cThe strong demand following legalisation in Germany led to supply bottlenecks for many manufacturers, which often made long-term cooperation difficult,\u2019 Antoniazzi said.\u00a0<\/p>\n

\u201cWith the Sanity Group and the Avaay Medical product line, we have now found the right partner. The combination of high product quality, professional structures, and reliable delivery capacity gives us the confidence that we can continue to offer our patients in Switzerland a first-class range of products and services.\u201d<\/p>\n

<\/p>\n

\n Adult-Use
\n Switzerland\u2019s Largest Cannabis Pilot Project to Date \u2018Perfect Sweet Spot\u2019 to Study Recreational With the Same Research-Based Approach as Medical
\n Switzerland\u2019s Federal Office of Public Health (FOHP) officially approved the \u2018Grashaus Project\u2019 last month, the country\u2019s sixth adult-use cannabis pilot study. This study represents a number of firsts for Switzerland\u2019s [\u2026]\n <\/p>\n

Read the Story \u2192
\n <\/a><\/p>\n

Switzerland a \u2018key market\u2019<\/p>\n

Sanity Group, which is already a key stakeholder in the ongoing Swiss adult-use pilot trials<\/a>, says Switzerland remains a key strategic and commercial priority.\u00a0<\/p>\n

\u201cSwitzerland is a key market for us in Europe, both in terms of medical care and with regard to modern regulatory approaches,\u201d said Leonhard Friedrich, Managing Director of Sanity Group Switzerland.<\/p>\n

The deal adds to a footprint in Switzerland that already includes Grashaus Projects<\/a>, the Sanity Group subsidiary operating two licensed cannabis retail stores in Basel-Landschaft canton as part of an adult-use scientific pilot.\u00a0<\/p>\n

Running since 2023 with 1,800 enrolled participants, approximately 3% of the canton\u2019s adult population, the programme is among the most mature in Europe. Across all eight Swiss pilots<\/a>, 66% of participants report they no longer source cannabis from illegal channels, according to data presented at the European Cannabis Insights Summit in Berlin last week.<\/a><\/p>\n

<\/p>\n

\n Data & Analysis
\n European Cannabis Insights Summit 2026: Patients & Politics Post-Reclassification
\n Since April 2024, Berlin has cemented its place as the spiritual centre of the European cannabis industry. It is home not only to the policymakers, institutions, and business leaders that [\u2026]\n <\/p>\n

Read the Story \u2192
\n <\/a><\/p>\n

Astrasana Holding AG operates across the full Swiss cannabis value chain, from cultivation and manufacturing to pharmacy distribution, with subsidiaries in Switzerland, the Czech Republic, the UK, and Japan.<\/p>\n

The deal forms part of\u00a0 Organigram\u2019s stated ambition, outlined at the time of its Sanity acquisition, to \u2018unlock significant growth opportunities as new European markets open to both medical and recreational cannabis programmes.\u2019<\/p>\n

Finn Age H\u00e4nsel, Co-Founder and CEO of Sanity Group, who remained in post following the acquisition\u2019s completion, spoke at the European Cannabis Insights Summit last week on the policy implications of Swiss pilot data for Germany\u2019s own regulatory trajectory.<\/p>\n

In this article<\/p>\n

\t\t\t
\n\t\t\t\t\t\t\t\t\tOR<\/p>\n

\t\t\t\t\tMore on
\n\t\t\t\t\tOrganigram Holdings<\/p>\n

\t\t\t\tView profile \u2192
\n\t\t\t<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Sanity Group has announced a new distribution partnership with Swiss cannabis operator Astrasana Holding AG, further expanding its…\n","protected":false},"author":2,"featured_media":86471,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4],"tags":[44101,44102,44103,44104,44105,18285,44106,44107,1344,44108,44109,41726,44110,44111,41,17,44112],"class_list":["post-86470","post","type-post","status-publish","format-standard","has-post-thumbnail","category-switzerland","tag-astrasana","tag-avaay-medical","tag-bogen-pharma","tag-cannabis-pilot","tag-cannabis-supply-chain","tag-distribution","tag-european-cannabis","tag-finn-age-hansel","tag-germany","tag-grashaus-projects","tag-leonhard-friedrich","tag-medical-cannabis","tag-organigram","tag-sanity-group","tag-swiss","tag-switzerland","tag-yves-antoniazzi"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116769172063583330","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/86470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=86470"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/86470\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/86471"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=86470"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=86470"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=86470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}